Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, 190006, J&K, India.
Department of Biotechnology, School of Life Sciences, Central University of Kashmir, Ganderbal, J&K, 191201, India.
Cancer Chemother Pharmacol. 2021 Feb;87(2):147-158. doi: 10.1007/s00280-020-04222-w. Epub 2021 Jan 9.
Breast cancer is presently the most predominant tumor type and the second leading cause of tumor-related deaths among women. Although advancements in diagnosis and therapeutics have momentously improved, chemoresistance remains an important challenge. Tumors oppose chemotherapeutic agents through a variety of mechanisms, with studies revealing that the tumor microenvironment (TME) is central to this process. The components of TME including stromal cells, immune cells, and non-stromal factors on exposure to chemotherapy promote the acquisition of resistant phenotype. Consequently, limited targeting of tumor cells leads to tumor recurrence after chemotherapy. Here, in this article, we summarize how TME alters chemotherapy responses in breast cancer. Furthermore, the role of different stromal cells viz., CAFs, TAMs, MSCs, endothelial cells, and cancer stem cells (CSC) in breast cancer chemoresistance is discussed in greater detail.
目前，乳腺癌是最常见的肿瘤类型，也是女性肿瘤相关死亡的第二大主要原因。尽管在诊断和治疗方面取得了重大进展，但化疗耐药仍然是一个重要的挑战。肿瘤通过多种机制来对抗化疗药物，研究表明肿瘤微环境（TME）在这一过程中起着核心作用。TME 的组成部分包括基质细胞、免疫细胞和非基质因素，它们在接触化疗药物后会促进耐药表型的获得。因此，对肿瘤细胞的有限靶向治疗导致化疗后肿瘤复发。在这里，本文总结了 TME 如何改变乳腺癌对化疗的反应。此外，还更详细地讨论了不同基质细胞（如 CAFs、TAMs、MSCs、内皮细胞和癌症干细胞（CSC））在乳腺癌化疗耐药中的作用。
